Contract Deobligations Alert — August 21, 2026

CACI won a $674.4M cost-plus-fixed-fee delivery order from GSA for IT and telecom services, with a total potential value of $722.6M over 5 years. The full-and-open competition win signals technical merit and pricing competitiveness, while cost-plus pricing provides low-risk, predictable revenue.

Teledyne Brown Engineering's $371.5M NASA contract for ISS mission support (2013-2022) has actual outlays of only $151.3M, less than half the obligated value, indicating potential under-execution or delayed spending. The contract has already ended, with zero future revenue contribution.

BARDA awarded a $263.6M obligation (potential $1.04B over 10 years) to the nonprofit Sabin Vaccine Institute for Marburg virus R&D. The cost-plus-fixed-fee structure reduces risk, but the nonprofit recipient limits direct investment implications, though subcontractors may benefit.

HSGS-AMERESCO, LLC won a $149.2M firm-fixed-price delivery order from the VA for energy savings performance contracts at two VAMCs. The SDVOSB set-aside limits competition, but fixed-price pricing introduces performance risk, with a 19-month execution window.

HIGHRISE Consulting Inc. secured a $138.6M delivery order from NIH for IT and cloud support (2022-2027), with $89.6M already outlayed (65% utilization). Labor-hours pricing and partial small business set-aside suggest stable margins and low cancellation risk.

Teledyne Brown's NASA ISS contract (2013-2022) has actual outlays of only $151.3M vs. $371.5M obligated, suggesting significant under-execution or delayed spending. This raises questions about Teledyne's ability to fully realize contract value and may indicate performance issues.

HSGS-AMERESCO's $149.2M VA energy contract is firm-fixed-price, which transfers cost overrun risk to the contractor. The 19-month performance window for hospital construction/renovation could face delays or change orders, potentially eroding margins.

The CACI $674M GSA contract has a negative net outlay (-$414,919), which is unusual and may indicate early-stage activity or accounting adjustments. This could signal delayed revenue recognition or contract modifications that affect profitability.

5 of 6 contracts are civilian agency awards (GSA, NASA, HHS, VA, NIH), with only one negligible defense-related award ($6K DHS). This creates concentration risk for investors seeking defense exposure, as the digest lacks DOD contract signals.

CACI's $674M GSA IT services win under full-and-open competition demonstrates strong competitive positioning in federal IT. The cost-plus pricing provides stable, low-risk revenue, and the 5-year duration offers visibility. Investors should watch for follow-on task orders and recompete opportunities.

HIGHRISE Consulting's $138.6M NIH cloud contract with 65% outlayed indicates strong execution and recurring revenue. The labor-hours pricing and partial small business set-aside suggest stable margins. Investors should monitor NIH's IT budget for renewal risk and additional task orders.

The Sabin Vaccine Institute's $1.04B BARDA contract for Marburg virus R&D signals sustained government investment in biodefense. While the prime is a nonprofit, publicly traded biotech firms and subcontractors could benefit from this program. Investors should track subcontract awards.

HSGS-AMERESCO's $149.2M VA energy contract is an SDVOSB set-aside, indicating policy-driven opportunities for veteran-owned small businesses in energy efficiency. This could signal a broader VA commitment to ESPC contracts, benefiting other SDVOSB firms in the sector.

Two major contracts—CACI's $674M GSA IT services and HIGHRISE's $138.6M NIH cloud support—demonstrate continued federal investment in IT modernization and cloud migration. Both are multi-year awards with cost-plus or labor-hours pricing, reducing earnings risk for contractors.

BARDA's $1.04B contract to the Sabin Vaccine Institute for Marburg virus R&D underscores sustained government commitment to biodefense, even as COVID-19 funding recedes. The 10-year performance period signals long-term program stability.

Teledyne Brown's $371.5M ISS support contract (2013-2022) has actual outlays of only $151.3M, suggesting under-execution. While the contract has ended, the gap between obligations and outlays raises questions about NASA's spending efficiency and contractor performance.

{"entity" => "CACI International Inc.", "reason" => "CACI's $674M GSA contract has a negative net outlay (-$414,919), which is unusual and may require clarification. The contract also ends May 2024, so recompete or extension announcements are critical.", "trigger" => "Contract recompete or extension announcement; negative outlay clarification in earnings calls"}

{"entity" => "Teledyne Technologies", "reason" => "Teledyne Brown's $371.5M NASA ISS contract has actual outlays of only $151.3M, indicating under-execution. The contract has ended, so follow-on awards or new NASA contracts are key to assessing future revenue.", "trigger" => "Follow-on NASA contract awards in mission operations or ISS payload support"}

{"entity" => "HSGS-AMERESCO, LLC", "reason" => "The $149.2M VA energy contract is firm-fixed-price with a 19-month performance window, creating execution risk. Option exercise by February 2027 is a key catalyst.", "trigger" => "Option exercise by February 2027; cost overrun or change order announcements"}

{"entity" => "Albert B. Sabin Vaccine Institute", "reason" => "The $1.04B BARDA contract for Marburg virus R&D has a 10-year performance period. Option exercise announcements and subcontract awards to publicly traded biotech firms are key catalysts.", "trigger" => "Option exercise announcements; subcontract awards to publicly traded biotech firms"}